The Thai National Center for Genetic Engineering predicts that two COVID-19 antiviral nasal drops will enter human trials by the end of this year.
Ratchada Thanadirek, a deputy government spokesman, said on Wednesday that nasal drops were based on adenovirus and flu, and testing in mice provided promising results.
The first phase of human clinical trials is expected to begin later this year after the pending approval has been approved by the national food and drug regulator.
The Thanadirek will also include the effectiveness of the spray on the Delta variant, with a second phase scheduled for March 2022 and, with good results, produced for widespread use in mid-2022. Said that it will be.
Research is underway in countries around the world to develop nasal drops that help prevent and treat the CCP virus, especially given that the nasal lining has been identified as an important entry point for the virus.
In a study of similar preclinical products, the developers argued that antiviral nasal drops could significantly reduce the infectivity of respiratory and cold viruses, including COVID-19. CCP (Chinese Communist Party) virus..
According to data released on July 27 by Australian-based company Starpharma That study Examination of Astodrimer Sodium (SPL7013) at the Scripps Research Institute in the United States revealed that the substance can inactivate more than 99% of CCP viruses, including Delta and Kappa variants.
The company also states that Viraleze nasal sprays are effective against other viruses such as RSV, SARS and MERS.
As of August 11, approximately 6.8% of Thailand’s population of over 66 million have been vaccinated twice.
Reuters and Rebecca Zhu contributed to this report.
from NTD News
